Biotech stock Auris Medical Holding AG (NASDAQ:EARS) reacted positively to the press release, which stated that the company has added ‘AM-125’, a third clinical-stage plan to its pipeline, which enabled it to move into the segment of vestibular disorders.
A look at biotech stock EARS price movement in the past 12-months demonstrates that the equity has underperformed the Zacks categorized Medical-Drugs segment. Specifically, Auris’ stock declined over 71% during this period, whereas the biotechnology stocks index dropped 2%.
Coming back to the biotech stock news, Auris will advance betahistine dihydrochloride as a spray preparation for the intranasal cure of vestibular vertigo and Meniere’s disease. Note that the firm had entered into a deal with Otifex Therapeutics Pty. Ltd. to buy numerous assets linked to intranasal betahistine, including clinical and preclinical data, and specific intellectual property rights.
Auris intends to commence a phase I trial on the candidate this year. Betahistine, a molecule drug which works as a H3-receptor antagonist and incomplete histamine H1-receptor agonist, is permitted for the treatment of vestibular vertigo and Meniere’s disease in more than 80 nations. Betahistine has been awaiting approval in the U.S.
More than 600,000 adults in the United States are presently diagnosed with Meniere’s disease. As of now there is no therapy permitted for Meniere’s disease in the United States, while treatment alternatives for vestibular disorders are extremely limited in the region.
Addition of AM-125 to company’s pipeline is a strategic step for its current projects. Going forward, they anticipate shareholders to focus on more updates from the firm on the Phase 1 trial.
Auris currently has a Zacks Rank #3. Some better-ranked biotech stocks comprise Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP), Eli Lilly and Co (NYSE:LLY) and Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS). While Sucampo has a Zacks Rank #1, Sunesis and Lilly boasts Zacks Rank #2.